Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company. The Company develops and commercializes therapeutics and medicines for the treatments and preventions for viral and bacterial diseases. Vir Biotechnology serves customers in the State of California.
Website: vir.bio



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 128.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +75.8%. On average the margin is improving steadily. Gross margin is high, +92.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.07 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 53.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 25.6% higher than minimum and 81.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued >100x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.2 mln (-0.027% of cap.)

Key Financials (Download financials)

Ticker: VIR
Share price, USD:  (-1.9%)5.65
year average price 7.45  


year start price 10.70 2024-07-27

max close price 12.48 2025-01-08

min close price 4.50 2025-05-14

current price 5.65 2025-07-26
Common stocks: 132 606 767

Dividend Yield:  0.0%
FCF Yield LTM: 53.9%
EV / LTM EBITDA: 500.0x
EV / Sales: -0.1x
Margin (EBITDA LTM / Revenue): 75.8%
Fundamental value created in LTM:
Market Cap ($m): 749
Net Debt ($m): -1 077
EV (Enterprise Value): -328
Price to Book: 0.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-07-23seekingalpha.com

Vir Biotechnology: Hep B And Cancer Projects March On

2025-05-07seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

2025-02-26seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

2025-01-09zacks.com

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

2025-01-09seekingalpha.com

Vir Biotechnology: A Rocket Off Phase 1 Data

2025-01-08businesswire.com

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

2024-12-13seekingalpha.com

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

2024-11-18businesswire.com

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

2024-10-31seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript

2024-10-31zacks.com

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-01 2024-05-03 2024-02-26 2023-11-03 2023-08-04 2023-05-08 2023-02-28 2022-11-03
acceptedDate 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 2M 3M 56M 17M -4M -13M 47M 22M 371M
costOfRevenue 50 000 4M 5M 5M 38 000 22 000 2M 6M 22M
grossProfit 2M -1M 52M 12M -4M -13M 45M 16M 349M
grossProfitRatio 0.979 -0.402 0.919 0.686 1.009 1.002 0.959 0.725 0.94
researchAndDevelopmentExpenses 195M 98M 68M 90M 148M 172M 158M 155M 114M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 26M 30M 36M 39M 41M 47M 47M 39M 43M
otherExpenses 11M -535 000 -287 000 -1M 882 000 -367 000 -16M -28M -3M
operatingExpenses 234M 128M 104M 129M 183M 202M 188M 166M 154M
costAndExpenses 232M 132M 109M 134M 183M 202M 190M 172M 176M
interestIncome 18M 19M 21M 21M 22M 23M 21M 16M 9M
interestExpense 0 0 0 239 000 0 0 -239 000 -10M 9M
depreciationAndAmortization 3M 4M 5M 43 812 3M 5M 13M -9M 14M
ebitda -216M -128M -48M -113M -184M -210M -130M -159M 209M
ebitdaratio -90.629 -40.685 -0.851 -6.71 44.906 16.515 -2.789 -7.315 0.561
operatingIncome -219M -129M -52M -117M -187M -215M -143M -151M 195M
operatingIncomeRatio -91.845 -42.07 -0.931 -6.977 45.567 16.914 -3.069 -6.907 0.525
totalOtherIncomeExpensesNet 5M 19M -13M -4M -2M -5M 183 000 -1M 23M
incomeBeforeTax -214M -140M -65M -121M -167M -198M -143M -152M 218M
incomeBeforeTaxRatio -89.723 -45.493 -1.153 -7.193 40.66 15.534 -3.065 -6.959 0.586
incomeTaxExpense 177 000 -2M 276 000 -5M -3M -3M -2M -50M 42M
netIncome -214M -138M -65M -116M -163M -195M -141M -102M 175M
netIncomeRatio -89.797 -45.001 -1.158 -6.909 39.876 15.31 -3.018 -4.663 0.472
eps -1.56 -1.02 -0.48 -0.86 -1.22 -1.45 -1.06 -0.76 1.32
epsdiluted -1.56 -1.02 -0.48 -0.86 -1.22 -1.45 -1.06 -0.76 1.3
weightedAverageShsOut 137M 136M 135M 135M 134M 134M 134M 133M 133M
weightedAverageShsOutDil 137M 136M 135M 135M 134M 134M 134M 133M 135M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-01 2024-05-03 2024-02-26 2023-11-03 2023-08-04 2023-05-08 2023-02-28 2022-11-03
acceptedDate 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 168M 311M 174M 255M 452M 667M 825M 849M 964M
shortTermInvestments 746M 854M 989M 1 281M 1 244M 1 180M 1 425M 1 553M 1 383M
cashAndShortTermInvestments 999M 1 165M 1 163M 1 536M 1 697M 1 847M 2 250M 2 402M 2 346M
netReceivables 0 7M 10M 12M 5M 0 0 0 0
inventory 0 1 0 0 8M 0 0 0 0
otherCurrentAssets 49M 79M 40M 41M 59M 86M 98M 104M 67M
totalCurrentAssets 1 047M 1 206M 1 213M 1 588M 1 769M 1 946M 2 359M 2 519M 2 414M
propertyPlantEquipmentNet 126M 128M 163M 167M 172M 179M 185M 188M 185M
goodwill 17M 17M 17M 17M 17M 17M 17M 17M 17M
intangibleAssets 19M 19M 22M 23M 25M 26M 33M 33M 33M
goodwillAndIntangibleAssets 36M 36M 39M 40M 42M 43M 50M 50M 50M
longTermInvestments 278M 286M 366M 112M 40M 52M 49M 24M 34M
taxAssets 0 0 0 41M 0 0 0 0 0
otherNonCurrentAssets 12M 13M 12M 12M 22M 24M 23M 21M 13M
totalNonCurrentAssets 451M 464M 581M 372M 276M 298M 307M 283M 282M
otherAssets 0 0 0 1 0 0 0 0 0
totalAssets 1 498M 1 670M 1 794M 1 960M 2 045M 2 244M 2 666M 2 802M 2 696M
accountPayables 7M 4M 7M 6M 4M 12M 12M 6M 3M
shortTermDebt 19M 19M 12M 13M 14M 14M 7M 4M 4M
taxPayables 0 17 000 146 000 149 000 15M 15M 15M 15M 98M
deferredRevenue 15M 17M 15M 65M 15M 16M 17M 16M 23M
otherCurrentLiabilities 75M 56M 60M 91M 133M 184M 449M 485M 279M
totalCurrentLiabilities 117M 96M 94M 175M 165M 226M 485M 511M 308M
longTermDebt 187M 95M 109M 112M 114M 118M 121M 124M 127M
deferredRevenueNonCurrent 0 0 2M 2M 53M 53M 53M 53M 55M
deferredTaxLiabilitiesNonCurrent 0 0 0 43M 0 0 3M 3M 18M
otherNonCurrentLiabilities -46M 44M 42M 38M 37M 37M 32M 33M 208M
totalNonCurrentLiabilities 140M 139M 153M 194M 205M 208M 210M 213M 238M
otherLiabilities 0 1 0 1 0 0 0 0 0
capitalLeaseObligations 113M 115M 109M 112M 114M 118M 121M 124M 127M
totalLiabilities 258M 236M 247M 370M 370M 434M 695M 724M 546M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 14 000 14 000 14 000 13 000 13 000 13 000 13 000 13 000 13 000
retainedEarnings -655M -441M -303M -238M -122M 42M 236M 377M 479M
accumulatedOtherComprehensiveIncomeLoss 1M -3M -2M -815 000 -2M -3M -3M -9M -12M
othertotalStockholdersEquity 1 895M 1 878M 1 853M 1 829M 1 799M 1 772M 1 738M 1 710M 1 683M
totalStockholdersEquity 1 241M 1 434M 1 547M 1 590M 1 675M 1 810M 1 971M 2 078M 2 150M
totalEquity 1 241M 1 434M 1 547M 1 590M 1 675M 1 810M 1 971M 2 078M 2 150M
totalLiabilitiesAndStockholdersEquity 1 498M 1 670M 1 794M 1 960M 2 045M 2 244M 2 666M 2 802M 2 696M
minorityInterest 0 0 0 0 0 0 44 000 0 0
totalLiabilitiesAndTotalEquity 1 498M 1 670M 1 794M 1 960M 2 045M 2 244M 2 666M 2 802M 2 696M
totalInvestments 1 024M 1 141M 1 355M 1 393M 1 273M 1 219M 1 456M 1 545M 1 417M
totalDebt 113M 115M 121M 125M 114M 118M 121M 128M 127M
netDebt -56M -196M -53M -130M -338M -549M -703M -721M -837M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VIR VIR VIR VIR VIR VIR VIR VIR VIR
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-04 2024-08-01 2024-05-03 2024-02-26 2023-11-03 2023-08-04 2023-05-08 2023-02-28 2022-11-03
acceptedDate 2024-11-04 16:09:50 2024-08-01 16:43:21 2024-05-03 16:16:53 2024-02-26 16:10:13 2023-11-03 16:05:44 2023-08-04 16:02:43 2023-05-08 16:06:26 2023-02-28 16:22:13 2022-11-03 16:08:24
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -214M -138M -65M -116M -163M -195M -141M -102M 175M
depreciationAndAmortization 3M 4M 5M 4M 5M 5M 6M 2M 2M
deferredIncomeTax 57 000 -363 000 0 -1M -167M 14M 0 -15M 0
stockBasedCompensation 17M 22M 24M 28M 27M 31M 25M 25M 25M
changeInWorkingCapital 17M -2M -82M -33M -30M -253M 11M 130M -55M
accountsReceivables -2M 3M -401 000 -4M -3M 948 000 2M 278M 58M
inventory 0 0 0 248M 3M -251M 0 0 0
accountsPayables 3M -3M 735 000 3M -8M -934 000 7M 3M -4M
otherWorkingCapital 17M -2M -82M -280M -22M -2M 2M -151M -109M
otherNonCashItems 5M 68M 42M 9M 172M 9M -27M -5M -29M
netCashProvidedByOperatingActivities -171M -78M -109M -108M -156M -389M -126M 35M 118M
investmentsInPropertyPlantAndEquipment -2M -666 000 -2M -2M -4M -9M -7M -13M -19M
acquisitionsNet -912 000 379 000 533 000 184M 55M 0 0 0 0
purchasesOfInvestments -240M -271M -563M -819M -503M -310M -385M -407M -728M
salesMaturitiesOfInvestments 362M 483M 593M 716M 448M 550M 489M 267M 85M
otherInvestingActivites 505 000 212M 533 000 -184M -55M 0 0 0 11 000
netCashUsedForInvestingActivites 119M 212M 28M -105M -59M 230M 98M -153M -663M
debtRepayment -40 000 -69 000 -69 000 -87 000 -66 000 -68 000 -66 000 -77 000 -59 000
commonStockIssued 71 000 3M 221 000 2M 343 000 0 2M 0 0
commonStockRepurchased 0 0 0 0 0 0 0 3M 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 71 000 3M 221 000 400 000 277 000 3M 100 000 -1M 2M
netCashUsedProvidedByFinancingActivities 31 000 3M 152 000 2M 277 000 3M 2M 2M 2M
effectOfForexChangesOnCash 0 0 0 -48M 48M 0 0 0 0
netChangeInCash -46M 137M -81M -210M -215M -156M -25M -116M -543M
cashAtEndOfPeriod 264M 311M 174M 255M 472M 687M 843M 868M 984M
cashAtBeginningOfPeriod 311M 174M 255M 465M 687M 843M 868M 984M 1 527M
operatingCashFlow -171M -78M -109M -108M -156M -389M -126M 35M 118M
capitalExpenditure -2M -666 000 -2M -2M -4M -9M -7M -13M -19M
freeCashFlow -174M -79M -111M -109M -160M -399M -133M 23M 99M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-03 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)

Press-releases

Show financial reports only

2024-10-31 20:05 ET
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-15 12:16 ET
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
2024-10-03 20:00 ET
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
2024-09-10 12:05 ET
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
2024-09-09 20:05 ET
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
2024-08-22 12:05 ET
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
2024-08-01 20:02 ET
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
2024-08-01 20:01 ET
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
2024-07-18 20:05 ET
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
2024-06-26 12:05 ET
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
2024-06-05 09:30 ET
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
2024-05-29 20:05 ET
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-29 12:05 ET
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
2024-05-23 20:05 ET
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
2024-05-22 12:05 ET
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
2024-05-21 12:17 ET
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
2024-05-13 23:21 ET
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
2024-05-02 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
2024-04-30 20:05 ET
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
2024-04-18 12:00 ET
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
2024-04-11 20:30 ET
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
2024-03-05 13:05 ET
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
2024-02-23 13:05 ET
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
2024-02-22 21:05 ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-20 21:30 ET
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
2024-02-01 21:05 ET
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
2023-12-13 21:05 ET
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
2023-12-06 21:05 ET
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
2023-11-13 13:00 ET
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
2023-11-10 13:00 ET
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
2023-11-08 13:05 ET
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
2023-11-02 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-10-30 12:00 ET
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
2023-10-12 20:05 ET
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
2023-10-11 12:00 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
2023-10-05 20:30 ET
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
2023-10-03 11:59 ET
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
2023-09-20 12:00 ET
Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
2023-08-29 20:30 ET
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
2023-08-03 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
2023-07-26 20:05 ET
Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023
2023-07-20 12:00 ET
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness
2023-06-29 13:00 ET
Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer
2023-06-24 09:30 ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
2023-06-07 06:13 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023
2023-06-05 20:05 ET
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
2023-05-17 20:05 ET
Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders
2023-05-15 12:00 ET
Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer
2023-05-11 12:30 ET
Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI
2023-05-04 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
2023-05-03 20:05 ET
Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference
2023-05-02 13:00 ET
Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention
2023-04-11 20:05 ET
Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference
2023-03-08 21:05 ET
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
2023-02-28 21:05 ET
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
2023-02-23 21:05 ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-22 13:30 ET
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
2023-02-16 21:05 ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
2023-02-16 13:30 ET
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
2023-02-13 21:45 ET
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
2023-01-25 13:29 ET
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
2023-01-03 21:05 ET
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 13:00 ET
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
2022-11-16 13:30 ET
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
2022-11-06 15:35 ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
2022-11-03 20:03 ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
2022-10-31 20:05 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
2022-10-28 22:06 ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
2022-10-18 12:00 ET
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
2022-10-11 20:03 ET
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
2022-10-04 12:00 ET
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
2022-09-22 12:00 ET
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
2022-09-06 20:05 ET
Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-09 20:02 ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
2022-07-21 20:05 ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
2022-07-14 12:30 ET
Vir Biotechnology Announces Transition of Chief Scientific Officer
2022-07-03 23:10 ET
Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
2022-06-25 11:00 ET
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
2022-06-08 11:33 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
2022-05-18 20:03 ET
Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details
2022-05-05 20:07 ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
2022-04-27 12:39 ET
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day
2022-04-21 20:05 ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2022 Financial Results on May 5, 2022
2022-04-13 20:02 ET
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day
2022-04-06 16:14 ET
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge
2022-04-04 20:02 ET
Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference
2022-03-29 22:43 ET
Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600
2022-03-25 20:04 ET
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
2022-03-02 21:02 ET
Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference
2022-02-24 21:03 ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-10 21:02 ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
2022-02-10 06:24 ET
Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2
2022-02-08 11:00 ET
Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
2022-01-13 14:05 ET
Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria
2022-01-13 14:02 ET
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
2022-01-11 12:12 ET
GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19
2022-01-04 21:02 ET
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-12-31 13:46 ET
Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement
2021-12-17 13:16 ET
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
2021-12-14 21:39 ET
Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies
2021-12-09 13:30 ET
Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection
2021-12-07 08:55 ET
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
2021-12-07 08:48 ET
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
2021-12-02 07:07 ET
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
2021-11-17 11:42 ET
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
2021-11-12 13:00 ET
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
2021-11-12 12:10 ET
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
2021-11-04 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2021 Financial Results
2021-11-04 12:14 ET
Section 32 Raises $740 Million Venture Fund
2021-10-21 20:05 ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial Results on November 4, 2021
2021-10-15 12:30 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
2021-10-06 20:05 ET
Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
2021-09-30 20:05 ET
Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
2021-09-08 20:05 ET
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-07 20:05 ET
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-23 12:30 ET
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
2021-08-05 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
2021-07-28 10:20 ET
GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
2021-07-22 20:05 ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
2021-07-15 12:30 ET
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
2021-06-25 12:50 ET
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
2021-06-21 11:06 ET
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
2021-06-14 12:00 ET
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Oral and Poster Presentations at EASL 2021
2021-06-02 20:05 ET
Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-26 22:57 ET
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives Emergency Use Authorization from the US FDA for Treatment of Mild-to-Moderate COVID-19 in High-Risk Adults and Pediatric Patients
2021-05-21 12:04 ET
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19
2021-05-10 20:05 ET
Vir Biotechnology Reminds Stockholders of 2021 Annual General Meeting Details
2021-05-07 09:53 ET
GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19
2021-05-06 20:05 ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
2021-04-22 20:01 ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021
2021-04-21 12:00 ET
Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
2021-04-21 12:00 ET
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
2021-04-15 13:50 ET
GSK and Vir Biotechnology Announce EMA Review of Dual-Action Monoclonal Antibody VIR-7831 for the Early Treatment of COVID-19
2021-04-08 12:30 ET
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
2021-04-06 20:01 ET
Vir Biotechnology to Present at the 20th Annual Needham Virtual Healthcare Conference
2021-04-05 12:00 ET
Vir Biotechnology Announces New Preclinical Research Demonstrating VIR-7831 Maintains Neutralizing Activity Against the SARS-CoV-2 California Variant
2021-03-29 12:30 ET
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
2021-03-29 12:30 ET
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
2021-03-26 12:30 ET
GSK and Vir Biotechnology Announce Submission of Emergency Use Authorization Request to FDA for VIR-7831 for the Early Treatment of COVID-19
2021-03-11 01:22 ET
Vir Biotechnology and GSK Announce VIR-7831 Reduces Hospitalization and Risk of Death in Early Treatment of Adults with COVID-19
2021-03-03 14:00 ET
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
2021-02-25 21:01 ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-17 12:04 ET
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
2021-02-11 21:01 ET
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
2021-02-01 13:00 ET
Vir Biotechnology Announces New Data Highlighting the Importance of Targeting Conserved Regions of the SARS-CoV-2 Spike Protein in the Development of Therapeutics
2021-01-27 11:45 ET
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
2021-01-27 11:45 ET
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
2021-01-26 13:00 ET
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
2021-01-12 13:00 ET
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
2021-01-12 13:00 ET
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
2021-01-12 08:00 ET
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
2021-01-06 13:00 ET
Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform
2021-01-05 13:00 ET
Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-17 21:01 ET
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
2020-12-10 13:00 ET
Vir Biotechnology Appoints Jeffrey Hatfield to its Board of Directors
2020-11-10 21:01 ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial Results
2020-11-06 13:00 ET
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439K
2020-10-27 20:01 ET
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
2020-10-21 12:00 ET
Vir Biotechnology Presents New Data on VIR-2482, the Company’s Investigational Monoclonal Antibody for the Prevention of Influenza A, at IDWeek 2020
2020-10-13 20:01 ET
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-Conference
2020-10-09 12:00 ET
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection
2020-10-06 12:18 ET
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19
2020-09-24 12:00 ET
Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell
2020-09-09 20:10 ET
Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference
2020-09-08 20:01 ET
Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference
2020-09-01 20:01 ET
Vir Biotechnology Appoints Janet Napolitano to its Board of Directors
2020-08-31 12:00 ET
Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment
2020-08-24 11:00 ET
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases
2020-08-20 12:00 ET
Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™
2020-08-11 20:01 ET
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
2020-07-28 20:01 ET
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020
2020-07-10 20:02 ET
Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors
2020-07-10 20:01 ET
Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-07-08 02:24 ET
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
2020-07-06 11:00 ET
Vir Biotechnology Announces Proposed Public Offering of Common Stock
2020-05-29 12:00 ET
Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment
2020-05-27 12:00 ET
Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
2020-05-18 09:05 ET
Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature
2020-05-12 20:01 ET
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
2020-05-08 20:01 ET
Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
2020-05-07 20:01 ET
Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference
2020-04-28 12:00 ET
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020
2020-04-15 20:01 ET
VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
2020-04-10 02:29 ET
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment
2020-04-08 11:00 ET
Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218
2020-04-06 12:01 ET
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
2020-03-30 11:00 ET
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
2020-03-26 20:01 ET
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-25 12:00 ET
Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
2020-03-12 12:00 ET
Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19
2020-03-11 12:00 ET
Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
2020-03-11 00:24 ET
Vir Biotechnology to Present at Barclays Global Healthcare Conference
2020-02-25 13:30 ET
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
2020-02-25 01:47 ET
Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference
2020-02-12 13:30 ET
Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2
2020-01-22 22:45 ET
Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus
2020-01-13 13:00 ET
Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference
2020-01-07 22:09 ET
Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference
2019-11-19 21:15 ET
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results
2019-10-10 23:41 ET
Vir Biotechnology Announces Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 8
2025-07-24 13:05 ET
Vir Biotechnology published news for 2025 q2
SEC form 8
2025-07-24 13:05 ET
Vir Biotechnology published news for 2025 q2
SEC form 8
2025-05-09 12:23 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-09 12:23 ET
Vir Biotechnology published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Vir Biotechnology published news for 2025 q1
SEC form 10
2025-05-07 21:33 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
Vir Biotechnology published news for 2025 q1
SEC form 8
2025-05-07 20:13 ET
Vir Biotechnology reported for 2025 q1
SEC form 10
2025-02-27 00:00 ET
Vir Biotechnology published news for 2024 q4
SEC form 10
2025-02-26 22:34 ET
Vir Biotechnology published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Vir Biotechnology published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
Vir Biotechnology reported for 2024 q4
SEC form 10
2024-11-04 16:09 ET
Vir Biotechnology reported for 2024 q3
SEC form 8
2024-10-31 16:20 ET
Vir Biotechnology published news for 2024 q3
SEC form 8
2024-10-31 16:20 ET
Vir Biotechnology reported for 2024 q3
SEC form 10
2024-08-01 16:43 ET
Vir Biotechnology reported for 2024 q2
SEC form 8
2024-08-01 16:10 ET
Vir Biotechnology published news for 2024 q2
SEC form 8
2024-08-01 16:10 ET
Vir Biotechnology reported for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Vir Biotechnology reported for 2024 q2
SEC form 10
2024-05-03 16:16 ET
Vir Biotechnology published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Vir Biotechnology published news for 2024 q1
SEC form 8
2024-05-02 16:09 ET
Vir Biotechnology published news for 2024 q1
SEC form 8
2024-05-02 16:09 ET
Vir Biotechnology reported for 2024 q1
SEC form 10
2024-02-26 00:00 ET
Vir Biotechnology published news for 2023 q4
SEC form 10
2023-11-03 16:05 ET
Vir Biotechnology reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Vir Biotechnology reported for 2023 q3
SEC form 8
2023-11-02 16:09 ET
Vir Biotechnology reported for 2023 q3
SEC form 10
2023-08-04 16:02 ET
Vir Biotechnology reported for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Vir Biotechnology reported for 2023 q2
SEC form 6
2023-08-03 16:14 ET
Vir Biotechnology reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Vir Biotechnology reported for 2023 q2
SEC form 6
2023-07-20 08:04 ET
Vir Biotechnology published news for 2023 q2
SEC form 8
2023-07-20 00:00 ET
Vir Biotechnology published news for 2023 q2
SEC form 10
2023-05-08 00:00 ET
Vir Biotechnology reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Vir Biotechnology reported for 2023 q1
SEC form 6
2023-03-10 21:45 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-03-08 16:06 ET
Vir Biotechnology published news for 2022 q4
SEC form 10
2023-02-28 16:22 ET
Vir Biotechnology reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Vir Biotechnology reported for 2022 q4
SEC form 6
2023-02-23 16:05 ET
Vir Biotechnology reported for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Vir Biotechnology reported for 2022 q4
SEC form 6
2023-02-22 08:41 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-02-16 08:36 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-02-13 16:31 ET
Vir Biotechnology published news for 2022 q4
SEC form 6
2023-01-25 08:33 ET
Vir Biotechnology published news for 2022 q4
SEC form 10
2022-11-03 16:08 ET
Vir Biotechnology reported for 2022 q3
SEC form 6
2022-11-03 16:06 ET
Vir Biotechnology reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Vir Biotechnology reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Vir Biotechnology reported for 2022 q3
SEC form 6
2022-10-04 08:23 ET
Vir Biotechnology published news for 2022 q3
SEC form 10
2022-08-09 16:12 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-08-09 16:08 ET
Vir Biotechnology reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Vir Biotechnology published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Vir Biotechnology reported for 2022 q2
SEC form 6
2022-08-04 08:07 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-07-14 08:34 ET
Vir Biotechnology published news for 2022 q2
SEC form 6
2022-06-03 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-24 16:07 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-20 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-05-05 16:09 ET
Vir Biotechnology published news for 2022 q1
SEC form 10
2022-05-05 16:07 ET
Vir Biotechnology reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Vir Biotechnology reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Vir Biotechnology reported for 2022 q1
SEC form 6
2022-04-07 16:08 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-04-07 16:06 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-04-05 17:19 ET
Vir Biotechnology published news for 2022 q1
SEC form 6
2022-03-25 16:10 ET
Vir Biotechnology published news for 2021 q4
SEC form 10
2022-02-28 16:16 ET
Vir Biotechnology published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Vir Biotechnology published news for 2021 q4
SEC form 6
2022-02-24 16:27 ET
Vir Biotechnology published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Vir Biotechnology published news for 2021 q4
SEC form 6
2021-12-22 16:06 ET
Vir Biotechnology published news for 2021 q3
SEC form 10
2021-11-04 16:08 ET
Vir Biotechnology published news for 2021 q3
SEC form 6
2021-11-04 16:07 ET
Vir Biotechnology published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Vir Biotechnology published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Vir Biotechnology published news for 2021 q3
SEC form 6
2021-09-29 17:13 ET
Vir Biotechnology published news for 2021 q2
SEC form 10
2021-08-05 16:16 ET
Vir Biotechnology published news for 2021 q2
SEC form 6
2021-08-05 16:14 ET
Vir Biotechnology published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Vir Biotechnology published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Vir Biotechnology published news for 2021 q2
SEC form 6
2021-06-28 06:07 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-27 16:55 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-24 17:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-21 15:38 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-05-06 16:24 ET
Vir Biotechnology published news for 2021 q1
SEC form 10
2021-05-06 16:06 ET
Vir Biotechnology published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-04-13 16:06 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-04-06 16:05 ET
Vir Biotechnology published news for 2021 q1
SEC form 6
2021-03-31 16:05 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-03-30 06:07 ET
Vir Biotechnology published news for 2020 q4
SEC form 10
2021-02-25 16:57 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-02-25 16:15 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-02-19 17:03 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-01-28 16:05 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2021-01-06 17:16 ET
Vir Biotechnology published news for 2020 q4
SEC form 6
2020-12-29 16:00 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-12-10 17:21 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-11-10 17:16 ET
Vir Biotechnology published news for 2020 q3
SEC form 10
2020-11-10 16:13 ET
Vir Biotechnology published news for 2020 q3
SEC form 6
2020-11-10 16:05 ET
Vir Biotechnology published news for 2020 q3